Bio-Me today has become part of the Medicen Microbiome Drug Metabolism working group, an international initiative by leading academic, pharma and institutions to address the need for better understanding of drug-microbiome interactions.
The working group initiated by the Medicen Paris Region cluster comprises a network of more than 30 academic groups, biotech companies, CROs and associations, and includes 10 of the major pharma companies.
Solving the challenges arising from drug-microbiome interactions
The aim is to apply excellence in innovation to solving the challenges arising from drug-microbiome interactions to help develop tomorrow’s therapeutic solutions.
“Bio-Me is excited to join this prestigious group of companies and leading scientists and important work for better, personalized healthcare in the future. We see that our PMP™ technology is perfectly suited to adapt information from this work into something that can have an immediate clinical relevance and improve patient care worldwide,” says Morten Isaksen, Founder of Bio-Me and its Chief Innovation Officer.